BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37127779)

  • 1. A Spike-Control Approach that Evaluates High Resolution Mass Spectrometry-Based Sequence Variant Analytical Method Performance for Therapeutic Proteins.
    Zhang J; Shih M; Yan H; O'Connor T; Ji C; Faustino PJ
    Pharm Res; 2023 Jun; 40(6):1425-1433. PubMed ID: 37127779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Highly Efficient Workflow for Detecting and Identifying Sequence Variants in Therapeutic Proteins with a High Resolution LC-MS/MS Method.
    Cadang L; Tam CYJ; Moore BN; Fichtl J; Yang F
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An optimized approach to the rapid assessment and detection of sequence variants in recombinant protein products.
    Brady LJ; Scott RA; Balland A
    Anal Bioanal Chem; 2015 May; 407(13):3851-60. PubMed ID: 25795027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking the Behavior of Monoclonal Antibody Product Quality Attributes Using a Multi-Attribute Method Workflow.
    Jakes C; Millán-Martín S; Carillo S; Scheffler K; Zaborowska I; Bones J
    J Am Soc Mass Spectrom; 2021 Aug; 32(8):1998-2012. PubMed ID: 33513021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimisation of the use of sliding window deconvolution for comprehensive characterisation of trastuzumab and adalimumab charge variants by native high resolution mass spectrometry.
    Millán-Martín S; Carillo S; Füssl F; Sutton J; Gazis P; Cook K; Scheffler K; Bones J
    Eur J Pharm Biopharm; 2021 Jan; 158():83-95. PubMed ID: 33212184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopharmaceutical Industry Practices for Sequence Variant Analyses of Recombinant Protein Therapeutics.
    Valliere-Douglass J; Marzilli L; Deora A; Du Z; He L; Kumar SR; Liu YH; Mueller HM; Nwosu C; Stults J; Wang Y; Yaghmour S; Zhou Y
    PDA J Pharm Sci Technol; 2019; 73(6):622-634. PubMed ID: 31209169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A general evidence-based sequence variant control limit for recombinant therapeutic protein development.
    Zhang A; Chen Z; Li M; Qiu H; Lawrence S; Bak H; Li N
    MAbs; 2020; 12(1):1791399. PubMed ID: 32744138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nano-scale liquid chromatography/mass spectrometry and on-the-fly orthogonal array optimization for quantification of therapeutic monoclonal antibodies and the application in preclinical analysis.
    Duan X; Dai L; Chen SC; Balthasar JP; Qu J
    J Chromatogr A; 2012 Aug; 1251():63-73. PubMed ID: 22770385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Qualification of a Quantitative Method for Monitoring Aspartate Isomerization of a Monoclonal Antibody by Focused Peptide Mapping.
    Cao M; Mo WD; Shannon A; Wei Z; Washabaugh M; Cash P
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):490-507. PubMed ID: 27091886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eliminating tyrosine sequence variants in CHO cell lines producing recombinant monoclonal antibodies.
    Feeney L; Carvalhal V; Yu XC; Chan B; Michels DA; Wang YJ; Shen A; Ressl J; Dusel B; Laird MW
    Biotechnol Bioeng; 2013 Apr; 110(4):1087-97. PubMed ID: 23108857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry.
    Qu M; An B; Shen S; Zhang M; Shen X; Duan X; Balthasar JP; Qu J
    Mass Spectrom Rev; 2017 Nov; 36(6):734-754. PubMed ID: 27097288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
    Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
    MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of a comprehensive, orthogonal approach to sequence variant analysis for biotherapeutics.
    Lin TJ; Beal KM; Brown PW; DeGruttola HS; Ly M; Wang W; Chu CH; Dufield RL; Casperson GF; Carroll JA; Friese OV; Figueroa B; Marzilli LA; Anderson K; Rouse JC
    MAbs; 2019 Jan; 11(1):1-12. PubMed ID: 30303443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A platform for characterizing therapeutic monoclonal antibody breakdown products by 2D chromatography and top-down mass spectrometry.
    Mazur MT; Seipert RS; Mahon D; Zhou Q; Liu T
    AAPS J; 2012 Sep; 14(3):530-41. PubMed ID: 22581105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward Accurate and Robust Liquid Chromatography-Mass Spectrometry-Based Quantification of Antibody Biotherapeutics in Tissues.
    An B; Zhang M; Pu J; Qu Y; Shen S; Zhou S; Ferrari L; Vazvaei F; Qu J
    Anal Chem; 2020 Nov; 92(22):15152-15161. PubMed ID: 33155467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification, characterization and control of a sequence variant in monoclonal antibody drug product: a case study.
    Thakur A; Nagpal R; Ghosh AK; Gadamshetty D; Nagapattinam S; Subbarao M; Rakshit S; Padiyar S; Sreenivas S; Govindappa N; Pai HV; Melarkode Subbaraman R
    Sci Rep; 2021 Jun; 11(1):13233. PubMed ID: 34168178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of sequence variants as biomarkers to analyze population dynamics in cloned cell lines.
    Lin TJ; Beal KM; DeGruttola HS; Brennan S; Marzilli LA; Anderson K
    Biotechnol Bioeng; 2017 Aug; 114(8):1744-1752. PubMed ID: 28369783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of drug-product-related impurities and variants of a therapeutic monoclonal antibody by higher energy C-trap dissociation mass spectrometry.
    Wang D; Wynne C; Gu F; Becker C; Zhao J; Mueller HM; Li H; Shameem M; Liu YH
    Anal Chem; 2015 Jan; 87(2):914-21. PubMed ID: 25513708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-attribute method performance profile for quality control of monoclonal antibody therapeutics.
    Hao Z; Moore B; Ren C; Sadek M; Macchi F; Yang L; Harris J; Yee L; Liu E; Tran V; Ninonuevo M; Chen Y; Yu C
    J Pharm Biomed Anal; 2021 Oct; 205():114330. PubMed ID: 34479173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass spectrometry-based multi-attribute method for mutation analysis in the early development of therapeutic proteins.
    Liu T; Li Y; Xu J; Guo Q; Zhu L; Fu T; Li J; Zhang D; Qian W; Zhou X; Guo H; Hou S
    J Pharm Biomed Anal; 2022 Oct; 220():115018. PubMed ID: 36030755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.